TMO vs UNH

TMO exhibits exceptional operational health with a Piotroski F-Score of 8/9, indicating strong financial stability and efficiency. However, the stock is currently trading at a significant premium, with a current price of $513.98 far exceeding both the Graham Number ($237.97) and the growth-based Intrinsic Value ($371.44). While analyst sentiment remains strongly bullish with a target of $647.38, this is countered by bearish insider activity and a negative technical trend. The outlook is balanced between high-quality fundamentals and a stretched valuation.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.